18 and older, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Standardized Uptake Value SUV(t)= C(t)/ID/BW; C(t) is Radioactivity Measured at the Time t, Decay Corrected to t=0 and Converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; W= Body Weight; SUV is Correct UMPrimary· approximatively 12 hours for Arm 1 only
To collect preliminary data regarding FDG biodistribution in the organs listed as a function of time of 12 hours. Time-activity curves will be created
Aorta
Group
Value
95% CI
Delayed Imaging Acquisition
0.83
± 0.47
Lungs
Group
Value
95% CI
Delayed Imaging Acquisition
0.48
± 0.44
Liver
Group
Value
95% CI
Delayed Imaging Acquisition
1.68
± 0.51
Spleen
Group
Value
95% CI
Delayed Imaging Acquisition
2.01
± 0.49
Kidneys
Group
Value
95% CI
Delayed Imaging Acquisition
1.91
± 0.83
Bone Marrow
Group
Value
95% CI
Delayed Imaging Acquisition
3.44
± 0.85
Skeletal Muscles
Group
Value
95% CI
Delayed Imaging Acquisition
1.23
± 0.44
Subcutaneous Fat
Group
Value
95% CI
Delayed Imaging Acquisition
0.25
± 0.21
Coefficient of Variation. SD/Mean (Standard Deviation Divided by Mean Value)Primary· approximatively 6 hours for Arm 1 only
To obtain preliminary data regarding low dose EXPLORER noise level
To collect preliminary data about total body FDG perfusion and early biodistribution. Time-activity curves will be created
Aorta
Group
Value
95% CI
Delayed Imaging Acquisition
1.75
± 0.34
Arm 2
0.88
± 0.17
Lungs
Group
Value
95% CI
Delayed Imaging Acquisition
0.62
± 0.37
Arm 2
0.32
± 0.06
Liver
Group
Value
95% CI
Delayed Imaging Acquisition
2.49
± 0.44
Arm 2
1.02
± 0.19
Spleen
Group
Value
95% CI
Delayed Imaging Acquisition
2.15
± 0.40
Arm 2
0.83
± 0.15
Kidneys
Group
Value
95% CI
Delayed Imaging Acquisition
3.65
± 1.85
Arm 2
1.45
± 0.23
Bone Marrow
Group
Value
95% CI
Delayed Imaging Acquisition
2.51
± 0.44
Arm 2
0.73
± 0.15
Skeletal Muscles
Group
Value
95% CI
Delayed Imaging Acquisition
0.70
± 0.19
Arm 2
0.37
± 0.06
Subcutaneous Fat
Group
Value
95% CI
Delayed Imaging Acquisition
0.19
± 0.05
Arm 2
0.19
± 0.04
Standardized Uptake Value SUV(t)= C(t)/(ID/BW); C(t) is Radioactivity Measured From at Time t, Decay Corrected to t=0-converted From a Volume to a Mass Based Unit Via the Factor 1/(1 g/mL); ID: the Injected Dose at t=0; BW= Body Weight; SUV is Correct UMPrimary· approximatively 3 hours
To obtain preliminary data to understand whether intravenous iodinated contrast agent produce a significant change in quantification of FDG uptake levels.
Time/activity curves will be generated.
Aorta
Group
Value
95% CI
Delayed Imaging Acquisition
1.18
± 0.30
Arm 2
0.39
± 0.08
Lungs
Group
Value
95% CI
Delayed Imaging Acquisition
0.52
± 0.53
Arm 2
0.15
± 0.04
Liver
Group
Value
95% CI
Delayed Imaging Acquisition
2.11
± 0.42
Arm 2
0.50
± 0.10
Spleen
Group
Value
95% CI
Delayed Imaging Acquisition
2.09
± 0.41
Arm 2
0.43
± 0.08
Kidneys
Group
Value
95% CI
Delayed Imaging Acquisition
3.30
± 1.34
Arm 2
0.66
± 0.12
Bone Marrow
Group
Value
95% CI
Delayed Imaging Acquisition
2.92
± 0.56
Arm 2
0.44
± 0.09
Skeletal Muscles
Group
Value
95% CI
Delayed Imaging Acquisition
0.82
± 0.21
Arm 2
0.21
± 0.04
Subcutaneous Fat
Group
Value
95% CI
Delayed Imaging Acquisition
0.16
± 0.05
Arm 2
0.07
± 0.02
Sponsor's own description
The objective of this pilot study is to collect preliminary data using total body scans on a new, first of its kind, FDA 510k-cleared positron emission tomography/computed tomography (PET/CT) scanner, called EXPLORER.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT04812080 — EXPLORER PET/CT: Evaluation of Healthy Individuals From Racial/Ethnic Minority Populations
· NA
· completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
NCT06707207 — Predicting Future Errors During Skill Performance
· recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
· Phase 1
· recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease.
· NA
· recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects
· NA
· recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity
· Phase 1, PHASE2
· recruiting
Other University of California, Davis trials
Trials by the same sponsor.
NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment
· NA
· not yet recruiting
NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)
· Phase 4
· recruiting
NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing
· Phase 2
· not yet recruiting
NCT07267494 — Image-Guided Herniorrhaphy Study
· NA
· not yet recruiting
NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants
· Phase 2, PHASE3
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
Last refreshed: 21 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04110743.